Trial Details
Not recruitingBasic Information
| Clinical ID | c3359 |
|---|---|
| Identifier | NCT00325078 |
| Trial Title | Tumor Necrosis Factor Alpha Inhibitor (Lnfliximab, Adalimumab) Treatment for Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease: A Phase I/II Study Assessing Clinical and Immune Responses to Treatment and Genetic Influences |
| Trial URL | Visit Original Page |
Study Information
| Study Results | Yes |
|---|---|
| Conditions | Chronic Granulomatous Disease;Crohn'S-like IBD;Inflammatory Bowel Disease (IBD);Chronic Granulomatous Disease;Crohn'S-like IBD;Inflammatory Bowel Disease (IBD);Chronic Granulomatous Disease;Crohn'S-like IBD;Inflammatory Bowel Disease (IBD);Chronic Granulomatous Disease;Crohn'S-like IBD;Inflammatory Bowel Disease (IBD) |
| Interventions | Drug: Infliximab;Drug: Infliximab;Drug: Infliximab;Drug: Infliximab |
Participant Information
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
|---|---|
| City | - |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | - |
Study Design
| Study Type | Interventional |
|---|---|
| Phase | PHASE1|PHASE2 |
Time Information
| Start Date | 2025-04-24 |
|---|---|
| Primary Completion Date | 2015-12-29 |
| Completion Date | - |